Vaccine-preventable | Chronic | Acute | |||||
---|---|---|---|---|---|---|---|
Compared clusters | 1996 | 2013 | 1996 | 2013 | 1996 | 2013 | |
Men | |||||||
SRR | 1.61 (1.48–1.74) | 1.77 (1.67–1.87) | 1.84 (1.77–1.92) | 1.91 (1.81–2.01) | 1.47 (1.35–1.59) | 1.61 (1.50–1.73) | |
N to SW | Rate | 1530/950 | 1750/990 | 5210/2820 | 1980/1030 | 1030/700 | 960/590 |
RD | 580 (460–700) | 760 (670–850) | 2380 (2190–2580) | 940 (840–1040) | 330 (250–410) | 360 (300–430) | |
SRR | 1.33 (1.23–1.44) | 1.51 (1.43–1.60) | 1.29 (1.24–1.35) | 1.32 (1.25–1.39) | 1.11 (1.02–1.21) | 1.25 (1.16–1.34) | |
N to C | Rate | 1530/1150 | 1750/1160 | 5210/4020 | 1980/1500 | 1030/930 | 960/770 |
RD | 380 (260–500) | 600 (500–690) | 1190 (990–1380) | 480 (380–570) | 100 (20–190) | 190 (120–260) | |
SRR | 1.21 (1.15–1.26) | 1.17 (1.13–1.21) | 1.42 (1.39–1.46) | 1.45 (1.41–1.50) | 1.32 (1.26–1.38) | 1.29 (1.25–1.35) | |
C to SW | Rate | 1150/950 | 1160/990 | 4020/2820 | 1500/1030 | 930/700 | 770/590 |
RD | 200 (150–240) | 170 (130–200) | 1200 (1120–1270) | 470 (430–500) | 220 (190–260) | 170 (150–200) | |
Women | |||||||
SRR | 1.52 (1.41–1.64) | 1.76 (1.67–1.87) | 1.92 (1.86–1.99) | 1.83 (1.75–1.91) | 1.48 (1.39–1.58) | 1.89 (1.78–2.00) | |
N to SW | Rate | 690/450 | 970/550 | 3520/1830 | 1490/820 | 860/580 | 1050/550 |
RD | 240 (190–290) | 420 (370–470) | 1690 (1580–1800) | 680 (610–740) | 280 (230–340) | 490 (430–550) | |
SRR | 1.31 (1.21–1.41) | 1.50 (1.41–1.59) | 1.30 (1.26–1.35) | 1.39 (1.33–1.46) | 1.10 (1.03–1.17) | 1.38 (1.30–1.47) | |
N to C | Rate | 690/530 | 970/650 | 3520/2710 | 1490/1070 | 860/790 | 1050/760 |
RD | 160 (110–210) | 320 (270–380) | 820 (700–930) | 420 (350–490) | 80 (20–130) | 290 (230–350) | |
SRR | 1.16 (1.11–1.22) | 1.18 (1.14–1.22) | 1.48 (1.45–1.51) | 1.31 (1.27–1.35) | 1.35 (1.30–1.41) | 1.37 (1.32–1.42) | |
C to SW | Rate | 530/450 | 650/550 | 2710/1830 | 1070/820 | 790/580 | 760/550 |
RD | 70 (50–100) | 100 (80–120) | 870 (820–930) | 250 (230–280) | 210 (180–230) | 200 (180–230) |